Research Program: Tumor Biology and Progression
Associate Professor of Medicine, Director of Clinical Trial Office in the Division of Hematology, Oncology, Transplantation

dudek002@umn.edu
612-624-6610, office
Preferred method of contact: e-mail
Assistant: Laura Connor, Tel: 612-624-5620, Fax: 612-625-6919, Email: conne171@umn.edu

Dr. Dudek is an Associate Professor and Director of the Clinical Trial Office in the Hematology, Oncology and Transplantation (HOT) Division. Dr. Dudek received his M.D. in 1989 from the Medical University of Warsaw, Poland. He received internal medicine residency training in Harrisburg, Pennsylvania and subspecialty training in Hematology, Oncology and Transplantation at the University of Minnesota. He received his Ph.D. from Military Medical Academy of Warsaw in 1998. He joined the faculty at the University of Minnesota in 1997.

Dr. Dudek's clinical profile
(University of Minnesota Physicians Web site)

Research Interests

Dr. Dudek's clinical interests include phase I and II clinical trials in solid tumors. His laboratory research is focused on cancer angiogenesis, tumor vaccines and preclinical novel drug testing.

Selected Publications

Dudek AZ, Pennell CA, Decker TD, Young TA, Key NS,  Slungaard A.  Platelet Factor 4 binds to glycanated forms of thrombomodulin and to 0rotein C; A potential mechanism for enhancing a generation of activated protein C.  J Biol Chem. 1997;272:31785-31792.

Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM. Origin of endothelial progenitors in human postnatal bone marrow.  J Clin Invest. 2003;109:337-346.

Dudek AZ, Nesmelova I, Mayo K, Verfaillie CM, Pitchford  S, Slungaard A.  Platelet factor 4 promotes adhesion of hematopoietic progenitors cells and binds interleukin 8: Novel mechanisms of modulation of hematopoiesis. Blood 2003;101:4687-4694.

Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ.  Bronchiolitis obliterans In recipients of bone marrow transplantation: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant. 2003;9:657-666.

Dudek AZ, Lesniewski-Kmak K, Bliss RL, Brunstein C, Condon DL, Kratzke RA. Pilot phase II study of gemcitabine and vinorelbine in patients with recurrent or refractory small cell lung cancer. Lung 2005;183:43-52.

Dudek AZ, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment responses and survival. Cancer Invest. 2005;23:193-200.

Dudek AZ, Arodz T, Galvez, J. Computational methods in developing quantitative structure-activity relationships (QSAR): A review. Comb Chem High Throughput Screen. 2006;9:213-28.

Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, Atkins MB, Whitman E, Ernstoff MS, Haluska FG, Jakowatz JG, Das Gupta TK, Richards JM, Samlowski WE, Costanzi JJ, Aronson FR, Deisseroth AB, Dudek AZ and Jones VE. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol. 2007;25:2078-85.

Dudek AZ, Bodempudi V, Milbauer L , Griffin RJ , Hebbel RP. Systemic inhibition of tumor angiogenesis by endothelial cell-based gene therapy. Br J Cancer 2007;97:513—522.

Dudek AZ, Zwolak P , Jasinski P, Terai Kaoru, Gallus NJ, Ericson ME, Farassati F. Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis. Invest New Drugs 2007;26:13-24.

Dudek AZ, Larson T, Keshtgarpour M, Kumar P. Dose escalating study of biweekly gemcitabine and carboplatin in patients with advanced cancer. Am J Clin Oncol. 2007;30:481-486.

Zwolak P, Dudek AZ, Bodempudi V, Nguyen J, Hebbel RP, Gallus NJ, Ericson ME, Goblirsch MJ, and Clohisy DR. Local irradiation in combination with bevacizumab enhances radiation control of bone destruction and cancer-induced pain in a model of bone metastases. Int J Cancer 2007;122:681-68.

Jasinski P, Welsh B, Galves J, Land D, Zwolak, P, Ghandi L, Terai K, Dudek AZ. A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines. Invest New Drugs 2007 [Epub ahead of print].

Dudek AZ, Yunis C, Harrison L, Kumar S, Hawkinson R, Cooley S, Vasilakos JP, Gorski KS, Miller JS. First in human phase I trial of 852A a novel systemic Toll-Like Receptor 7 agonist to activate innate immune responses in patients with advanced cancer. Clin Cancer Res. 2007;13:7119-7125.

Arodz T, Dudek AZ. Multivariate modeling and analysis in drug discovery. Current Computer-Aided Drug Design 2007;3:240-247.

Dudek AZ, Larson T, McCleod MJ, Schneider DJ, Dowell JE, Banerjee TK, Pandya KJ, Bromund JL, Chen R, Monberg MJ, Obasaju CK. Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer. J Thorac Oncol. 2008;3:394-399.

Dudek AZ, Mescher MF, Okazaki I, Math VT, Luo X, Curtsinger JM, Miller JS. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma. Am J Clin Oncol. 2008;31:173-181.

Jasinski P, Terai K, Zwolak P, Dudek AZ. Enzastaurin renders MCF-7 breast cancer cells sensitive to radiation through reversal of radiation-induced activation of protein kinase C. Eur J Cancer. 2008;44:1315-1322.